ARLINGTON, Va., Jan. 13 /PRNewswire/ -- BioInformatics, LLC announces the pending release of its newest report, The Contract Research Market for Drug Discovery Technologies: Opportunities for Life Science Suppliers. As lab budgets remain constricted, pharmaceutical and biotech labs are outsourcing pre-clinical and drug discovery services to create efficiency and offload the need to maintain staff, instruments and consumables for irregularly scheduled projects and projects that extend beyond their scope. This report was designed to provide guidance to the life science supplier as to the relationship between the pharmaceutical/biotech industries and Contract Research Organizations (CROs) -- and how capitalizing on fluctuations in outsourcing, the types of projects and tools purchased represents an opportunity that can steadily impact revenues. The report is scheduled to release in February, and is available at pre-release pricing until January 31, 2010. The Contract Research Market for Drug Discovery Technologies: Opportunities for Life Science Suppliers, includes detailed responses from over 100 scientists from CROs and over 100 scientists from Industry labs outsourcing to CROs to understand buying habits, criteria for making decisions, current vendors and purchases planned for 2010. Suppliers can use this report to characterize the potential of the preclinical CRO market, project the size and share of the CRO market for both consumables and instrumentation for 2010, and identify opportunities for capturing CRO market share. In this report, scientists also indicate planned instrument and consumable purchases by vendor. The following suppliers were provided as some of the choices in the survey: Thermo Fisher Scientific (NYSE:TMO) Agilent Technologies BD Biosciences (NYSE:BDX) Bio-Rad (NYSE:BIO) Beckman Coulter (NYSE:BEC) Life Technologies (NASDAQ:LIFE) Millipore (NYSE:MIL) GE Healthcare (NYSE:GE) PerkinElmer (NYSE:PKI) Qiagen (NASDAQ:QGEN) Roche Applied Science Sigma-Aldrich (NASDAQ:SIAL) Waters Corporation "This report provides direction for suppliers seeking to identify key purchasing decision points along the outsourcing chain," states Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. Dr. Zemlo further notes that "The appendix in the report features a comprehensive directory of CROs, which life science suppliers can use to develop key marketing and sales contacts within these organizations." To learn more about this report, a complimentary Executive Summary is available at http://www.gene2drug.com/reports/206/. ABOUT BIOINFORMATICS, LLC BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 46,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning. For more information contact: Mary Follin Manager, Marketing/Sales BioInformatics, LLC 2111 Wilson Blvd., Suite 250 Arlington, VA 22201 703.778.3080 x13 (phone) http://www.gene2drug.com/ DATASOURCE: BioInformatics, LLC CONTACT: Mary Follin, Manager, Marketing-Sales, BioInformatics, LLC, +1-703-778-3080 ext. 13, Web Site: http://www.gene2drug.com/

Copyright